RSS   Newsletter   Contact   Advertise with us

Circassia appoints new directors

Share on Twitter Share on LinkedIn
Staff Writer | Oxford, United Kingdom | February 14, 2018
Circassia PharmaceuticalsCircassia Pharmaceuticals, a specialty pharmaceutical company focused on respiratory disease, announces appointments to its board of directors.
Jo Le Couilliard was most recently Senior Vice President, Global Commercial Transformation at GlaxoSmithKline, and brings significant commercial and international pharmaceutical industry experience to Circassia.

Ms. Le Couilliard was previously a Non-Executive Director of the Frimley Park Hospital NHS Foundation Trust.

Sharon Curran was most recently Vice President, Global Specialty Franchise and Customer Excellence at Abbvie Inc.

Ms. Curran brings extensive commercial and specialty pharmaceutical experience to the Company having held a number of senior roles at Abbvie, Abbott and Eli Lilly.

Heribert Staudinger is currently Immunology Clinical Lead at Sanofi Genzyme and brings extensive respiratory medicine development expertise to Circassia.

During his 30 year career in pharmaceutical development Dr. Staudinger has held a number of leadership roles at Boehringer Ingelheim, Chiesi, Merck and Schering Plough.


 LATEST MOVES FROM United Kingdom 


MORE INSIDE POST